XBiotech Inc. Amends 8-K Filing on Officer/Director Changes

Ticker: XBIT · Form: 8-K/A · Filed: Oct 15, 2025 · CIK: 1626878

Xbiotech Inc. 8-K/A Filing Summary
FieldDetail
CompanyXbiotech Inc. (XBIT)
Form Type8-K/A
Filed DateOct 15, 2025
Risk Levelmedium
Pages1
Reading Time2 min
Sentimentneutral

Sentiment: neutral

Topics: corporate-governance, officer-changes, director-changes, amendment

Related Tickers: XBI

TL;DR

XBiotech filed an amendment to its 8-K, updating info on exec and director changes from June 24.

AI Summary

XBiotech Inc. filed an 8-K/A on October 15, 2025, to amend a previous filing regarding events that occurred on June 24, 2025. The amendment pertains to the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers.

Why It Matters

This filing indicates potential changes in the leadership structure or compensation of key personnel at XBiotech Inc., which could impact the company's strategic direction and governance.

Risk Assessment

Risk Level: medium — Amendments to 8-K filings concerning officer and director changes can signal internal shifts that may affect company strategy or stability.

Key Players & Entities

  • XBiotech Inc. (company) — Registrant
  • June 24, 2025 (date) — Date of earliest event reported
  • October 15, 2025 (date) — Date of report

FAQ

What specific events on June 24, 2025, are being amended in this 8-K/A filing?

The filing amends information related to the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers.

What is the exact date of the original event being reported or amended?

The earliest event reported or amended occurred on June 24, 2025.

What is the filing date of this amended 8-K report?

This Form 8-K/A was filed as of October 15, 2025.

What is the primary purpose of an 8-K/A filing?

An 8-K/A filing is used to amend a previously filed Current Report on Form 8-K.

What are the key areas of information covered by this amendment?

The amendment covers changes in directors or officers, elections, appointments, and executive compensation arrangements.

Filing Stats: 419 words · 2 min read · ~1 pages · Grade level 12 · Accepted 2025-10-15 12:54:38

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 15, 2025 XBIOTECH INC. By: /s/John Simard John Simard Chief Executive Officer and President

View Full Filing

View this 8-K/A filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.